{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:07:41Z","timestamp":1780376861051,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pegylated interferon alfa-2b (PEG-IFN\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b) is a first-line treatment for achieving functional cure in chronic hepatitis B (CHB). Although neuropsychiatric adverse events such as depression and sleep disturbances are well-documented with PEG-IFN\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b treatment, manic episodes are exceptionally rare, especially in CHB patients with no prior psychiatric risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A middle-aged male CHB patient with no personal or family history of mental disorders developed a manic episode at week 33 of PEG-IFN\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b therapy. He was initially managed at a psychiatric hospital, then transferred to our hepatology department due to interferon-related thrombocytopenia. A multidisciplinary team (MDT) comprising hepatologists, psychiatrists, neurologists, and pharmacists conducted an etiological investigation, which confirmed a high likelihood of PEG-IFN\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b-induced manic episode.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcomes<\/jats:title>\n                    <jats:p>\n                      Discontinuing PEG-IFN \u03b1-2b and initiating targeted antipsychotic treatment led to rapid resolution of psychiatric symptoms and recovery of platelet count. At the 2-week follow-up, the patient\u2019s mood was stable with a Young Mania Rating Scale score of 4, and his platelet count recovered to 334\u202f\u00d7\u202f10\n                      <jats:sup>9<\/jats:sup>\n                      \/L by week 36 of follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Manic episodes can occur during PEG-IFN\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -2b therapy for CHB even in patients without psychiatric risk factors. Clinicians should remain vigilant for this rare adverse event and implement routine mental health monitoring. MDT collaboration is critical for accurate etiological diagnosis and optimal management, ensuring a balance between pursuing functional cure and safeguarding treatment safety.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1849394","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:42Z","timestamp":1780374522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Probable manic episode induced by PEG-IFN \u03b1-2b in a chronic hepatitis B patient\u2014multidisciplinary management insights"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao-Cui","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Tian","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Lan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref1","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.3350\/cmh.2024.0780","article-title":"Update on the treatment navigation for functional cure of chronic hepatitis B: expert consensus 2.0","volume":"31","author":"Wu","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.psym.2017.09.007","article-title":"Interferon-induced mania in chronic viral hepatitis: a systematic review","volume":"59","author":"Malek","year":"2018","journal-title":"Psychosomatics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0033-3182(01)71213-0","article-title":"Interferon-induced mania in hepatitis C","volume":"42","author":"Horowitz","year":"2001","journal-title":"Psychosomatics"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/01.jcp.0000095263.21330.8c","article-title":"Interferon-alpha-induced mania in a patient with chronic hepatitis C","volume":"23","author":"Pantaleo","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pnpbp.2003.07.004","article-title":"Interferon alpha-induced mania in a patient with chronic hepatitis C","volume":"28","author":"Adalioglu","year":"2004","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0168-8278(02)00177-3","article-title":"Adverse neuropsychiatric effects of interferon-alpha therapy in patients with chronic hepatitis C","volume":"37","author":"Schaefer","year":"2002","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"ref12","first-page":"999","article-title":"Interferon alpha-induced mania in chronic hepatitis B","volume":"25","author":"Lieby","year":"2001","journal-title":"Gastroenterol Clin Biol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00004836-200303000-00022","article-title":"Interferon alpha-induced mania in chronic hepatitis B","volume":"36","author":"Pardo","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-2008-1049239","article-title":"Side effects of alpha interferon","volume":"9","author":"Renault","year":"1989","journal-title":"Semin Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.psym.2017.09.007","article-title":"Interferon-induced mania in chronic viral hepatitis: a systematic review","volume":"59","author":"Malek","year":"2018","journal-title":"Psychosomatics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0006-3223(99)00264-9","article-title":"Early depressive symptoms in cancer patients receiving interleukin 2 and\/or interferon alfa-2b: possible role of proinflammatory cytokines","volume":"47","author":"Capuron","year":"2000","journal-title":"Biol Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/npp.2012.97","article-title":"Neuroinflammation and psychiatric illness","volume":"37","author":"Meyer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","article-title":"Cytokines sing the blues: inflammation and the pathogenesis of depression","volume":"27","author":"Raison","year":"2006","journal-title":"Trends Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/nrn2513","article-title":"Why do many psychiatric disorders emerge during adolescence?","volume":"9","author":"Paus","year":"2008","journal-title":"Nat Rev Neurosci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1849394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:45Z","timestamp":1780374525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1849394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":21,"alternative-id":["10.3389\/fmed.2026.1849394"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1849394","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1849394"}}